South Denver Cardiology
Back to Trials

Dal-GenE

Short Description

Study to evaluate the effect of dalcetrapib on CV risk... with ACS

Dal-GenE: A phase III, double-blind, randomized placebo-controlled study to evaluate the effect of

dalcetrapib on CV risk in a genetically defined population with a recent ACS.

Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275

South Denver Cardiology

Recommend

  • This field is for validation purposes and should be left unchanged.
  • MM slash DD slash YYYY
  • What questions do you have regarding your bill?